Next Article in Journal
Next Article in Special Issue
Previous Article in Journal
Previous Article in Special Issue
Int. J. Mol. Sci. 2012, 13(12), 15536-15564; doi:10.3390/ijms131215536
Article

Cancer Cell Response to Anthracyclines Effects: Mysteries of the Hidden Proteins Associated with These Drugs

1
, 1
, 1
, 2
, 3
, 3
, 3
, 4
 and 1,*
Received: 31 August 2012; in revised form: 26 October 2012 / Accepted: 7 November 2012 / Published: 22 November 2012
(This article belongs to the collection Advances in Proteomic Research)
View Full-Text   |   Download PDF [2962 KB, updated 19 June 2014; original version uploaded 19 June 2014]
Abstract: A comprehensive proteome map of T-lymphoblastic leukemia cells and its alterations after daunorubicin, doxorubicin and mitoxantrone treatments was monitored and evaluated either by paired comparison with relevant untreated control and using multivariate classification of treated and untreated samples. With the main focus on early time intervals when the influence of apoptosis is minimized, we found significantly different levels of proteins, which corresponded to 1%–2% of the total amount of protein spots detected. According to Gene Ontology classification of biological processes, the highest representation of identified proteins for all three drugs belong to metabolic processes of proteins and nucleic acids and cellular processes, mainly cytoskeleton organisation and ubiquitin-proteasome pathway. Importantly, we observed significant proportion of changes in proteins involved in the generation of precursor metabolites and energy typical for daunorubicin, transport proteins participating in response to doxorubicin and a group of proteins of immune system characterising response to mitoxantrone. Both a paired comparison and the multivariate evaluation of quantitative data revealed daunorubicin as a distinct member of the group of anthracycline/anthracenedione drugs. A combination of identified drug specific protein changes, which may help to explain anti-cancer activity, together with the benefit of blocking activation of adaptive cancer pathways, presents important approaches to improving treatment outcomes in cancer.
Keywords: anthracycline/anthracenedione; T-lymphoblastic leukemia; proteomics; early anti-cancer response; adaptive cancer mechanisms; protein biosynthesis; ubiquitin-proteasome system; energy metabolism; transport proteins; tumor immunity anthracycline/anthracenedione; T-lymphoblastic leukemia; proteomics; early anti-cancer response; adaptive cancer mechanisms; protein biosynthesis; ubiquitin-proteasome system; energy metabolism; transport proteins; tumor immunity
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Export to BibTeX |
EndNote


MDPI and ACS Style

Tyleckova, J.; Hrabakova, R.; Mairychova, K.; Halada, P.; Radova, L.; Dzubak, P.; Hajduch, M.; Gadher, S.J.; Kovarova, H. Cancer Cell Response to Anthracyclines Effects: Mysteries of the Hidden Proteins Associated with These Drugs. Int. J. Mol. Sci. 2012, 13, 15536-15564.

AMA Style

Tyleckova J, Hrabakova R, Mairychova K, Halada P, Radova L, Dzubak P, Hajduch M, Gadher SJ, Kovarova H. Cancer Cell Response to Anthracyclines Effects: Mysteries of the Hidden Proteins Associated with These Drugs. International Journal of Molecular Sciences. 2012; 13(12):15536-15564.

Chicago/Turabian Style

Tyleckova, Jirina; Hrabakova, Rita; Mairychova, Katerina; Halada, Petr; Radova, Lenka; Dzubak, Petr; Hajduch, Marian; Gadher, Suresh J.; Kovarova, Hana. 2012. "Cancer Cell Response to Anthracyclines Effects: Mysteries of the Hidden Proteins Associated with These Drugs." Int. J. Mol. Sci. 13, no. 12: 15536-15564.


Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert